— Know what they know.
Not Investment Advice

RLMD NASDAQ

Relmada Therapeutics, Inc.
1W: -6.0% 1M: -20.7% 3M: -43.1% YTD: -17.6% 1Y: +66.7% 3Y: +357.1% 5Y: -38.1%
$3.60
-0.06 (-1.64%)
 
Weekly Expected Move ±9.0%
$3 $3 $4 $4 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 29 · $377.6M mcap · 90M float · 1.74% daily turnover · Short 54% of daily vol

Balance Sheet Trends

Total Assets
$94M +105.2% ▲
5Y CAGR: -4.5%
Total Liabilities
$7M -27.2% ▼
5Y CAGR: -9.9%
Shareholders Equity
$87M +143.5% ▲
5Y CAGR: -3.9%
Cash & Investments
$93M +107.1% ▲
5Y CAGR: -4.5%
Total Debt
$0 +0.0% ▲
Net Debt
-$3M +9.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$44M$5M$4M$4M$3M
Short-Term Investments$167M$143M$92M$41M$90M
Cash & ST Investments$212M$148M$96M$45M$93M
Net Receivables$86K$512K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$35$0$0$0$0
Total Current Assets$223M$153M$98M$46M$94M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$28K$35K$43K$22K$20K
Total Non-Current Assets$28K$35K$43K$22K$20K
Total Assets$223M$153M$98M$46M$94M
— Liabilities —
Accounts Payable$11M$5M$4M$4M$2M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$1M$6M$1M$5M
Total Current Liabilities$15M$12M$12M$10M$6M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$4K$1M
Total Non-Current Liabilities$0$0$0$4K$1M
Total Liabilities$15M$12M$12M$10M$7M
— Equity —
Common Stock$28K$30K$30K$30K$73K
Retained Earnings-$305M-$462M-$561M-$641M-$698M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$208M$140M$85M$36M$87M
Total Liabilities & Equity$223M$153M$98M$46M$94M
— Key Metrics —
Total Debt$0$0$0$0$0
Net Debt-$44M-$5M-$4M-$4M-$3M
Total Investments$167M$143M$92M$41M$90M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms